MOKAN Wealth Management Inc. Acquires 3,072 Shares of Gilead Sciences, Inc. $GILD

Key Points

• MOKAN Wealth Management Inc. increased its stake in Gilead Sciences, acquiring an additional 3,072 shares and bringing its total holdings to 19,352 shares, representing an 18.9% increase during the second quarter.
• Gilead Sciences reported $2.01 earnings per share for the recent quarter, exceeding expectations, with a revenue of $7.08 billion, which was also above consensus estimates.
• The company declared a quarterly dividend of $0.79 per share, resulting in an annualized dividend yield of 2.7%, reflecting a payout ratio of 62.95%.

MOKAN Wealth Management Inc. lifted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 18.9% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 19,352 shares of the biopharmaceutical company's stock after acquiring an additional 3,072 shares during the quarter. Gilead Sciences makes up 1.2% of MOKAN Wealth Management Inc.'s portfolio, making the stock its 26th biggest position. MOKAN Wealth Management Inc.'s holdings in Gilead Sciences were worth $2,146,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Smallwood Wealth Investment Management LLC bought a new position in shares of Gilead Sciences during the first quarter valued at approximately $25,000. Activest Wealth Management raised its holdings in Gilead Sciences by 2,837.5% in the first quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company's stock worth $26,000 after purchasing an additional 227 shares in the last quarter. Goodman Advisory Group LLC bought a new position in Gilead Sciences in the first quarter worth $29,000. Colonial Trust Advisors raised its holdings in Gilead Sciences by 304.3% in the first quarter. Colonial Trust Advisors now owns 283 shares of the biopharmaceutical company's stock worth $32,000 after purchasing an additional 213 shares in the last quarter. Finally, Core Alternative Capital raised its holdings in Gilead Sciences by 370.8% in the first quarter. Core Alternative Capital now owns 306 shares of the biopharmaceutical company's stock worth $34,000 after purchasing an additional 241 shares in the last quarter. Institutional investors own 83.67% of the company's stock.

Gilead Sciences Price Performance

Shares of NASDAQ:GILD opened at $117.18 on Monday. Gilead Sciences, Inc. has a 1-year low of $84.17 and a 1-year high of $121.83. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.32 and a quick ratio of 1.15. The business has a fifty day moving average price of $114.65 and a 200-day moving average price of $110.25. The company has a market capitalization of $145.40 billion, a PE ratio of 23.34, a PEG ratio of 0.80 and a beta of 0.34.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, beating the consensus estimate of $1.96 by $0.05. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The firm had revenue of $7.08 billion during the quarter, compared to the consensus estimate of $6.95 billion. During the same period last year, the company earned $2.01 earnings per share. The company's revenue was up 1.4% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. As a group, equities analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, September 29th. Investors of record on Monday, September 15th were given a dividend of $0.79 per share. The ex-dividend date of this dividend was Monday, September 15th. This represents a $3.16 annualized dividend and a dividend yield of 2.7%. Gilead Sciences's dividend payout ratio (DPR) is 62.95%.

Insider Activity at Gilead Sciences

In related news, CEO Daniel Patrick O'day sold 10,000 shares of the stock in a transaction on Monday, September 29th. The stock was sold at an average price of $111.66, for a total transaction of $1,116,600.00. Following the sale, the chief executive officer directly owned 591,203 shares of the company's stock, valued at $66,013,726.98. This trade represents a 1.66% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction on Monday, September 15th. The shares were sold at an average price of $113.57, for a total value of $283,925.00. Following the sale, the chief financial officer directly owned 159,555 shares in the company, valued at $18,120,661.35. This trade represents a 1.54% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 77,000 shares of company stock valued at $8,853,430 over the last ninety days. Insiders own 0.27% of the company's stock.

Analyst Ratings Changes

A number of equities analysts have issued reports on the company. Weiss Ratings reiterated a "buy (b)" rating on shares of Gilead Sciences in a report on Wednesday, October 8th. Truist Financial upgraded Gilead Sciences from a "hold" rating to a "buy" rating and increased their price objective for the stock from $108.00 to $127.00 in a report on Friday, August 8th. UBS Group increased their price objective on Gilead Sciences from $108.00 to $112.00 and gave the stock a "neutral" rating in a report on Friday, August 8th. Needham & Company LLC upgraded Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 price objective for the company in a report on Friday, July 25th. Finally, JPMorgan Chase & Co. increased their price objective on Gilead Sciences from $135.00 to $145.00 and gave the stock an "overweight" rating in a report on Tuesday, September 16th. Two analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and six have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, Gilead Sciences currently has an average rating of "Moderate Buy" and an average price target of $118.08.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.